RhumbLine Advisers’s Caribou Biosciences CRBU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-116,590
| Closed | -$106K | – | 4164 |
|
|
2025
Q1 | $106K | Sell |
116,590
-11,869
| -9% | -$10.8K | ﹤0.01% | 3372 |
|
|
2024
Q4 | $204K | Buy |
128,459
+1,535
| +1% | +$2.44K | ﹤0.01% | 3189 |
|
|
2024
Q3 | $249K | Buy |
126,924
+2,009
| +2% | +$3.94K | ﹤0.01% | 3126 |
|
|
2024
Q2 | $205K | Buy |
124,915
+2,398
| +2% | +$3.93K | ﹤0.01% | 3212 |
|
|
2024
Q1 | $630K | Buy |
122,517
+3,455
| +3% | +$17.8K | ﹤0.01% | 2519 |
|
|
2023
Q4 | $682K | Buy |
119,062
+10,864
| +10% | +$62.3K | ﹤0.01% | 2486 |
|
|
2023
Q3 | $517K | Buy |
108,198
+21,686
| +25% | +$104K | ﹤0.01% | 2594 |
|
|
2023
Q2 | $368K | Sell |
86,512
-961
| -1% | -$4.08K | ﹤0.01% | 2883 |
|
|
2023
Q1 | $464K | Buy |
87,473
+2,255
| +3% | +$12K | ﹤0.01% | 2473 |
|
|
2022
Q4 | $535K | Buy |
85,218
+350
| +0.4% | +$2.2K | ﹤0.01% | 2433 |
|
|
2022
Q3 | $895K | Buy |
84,868
+8,530
| +11% | +$90K | ﹤0.01% | 2188 |
|
|
2022
Q2 | $415K | Buy |
76,338
+27,980
| +58% | +$152K | ﹤0.01% | 2590 |
|
|
2022
Q1 | $444K | Buy |
48,358
+28,633
| +145% | +$263K | ﹤0.01% | 2477 |
|
|
2021
Q4 | $298K | Buy |
19,725
+2,126
| +12% | +$32.1K | ﹤0.01% | 2706 |
|
|
2021
Q3 | $420K | Buy |
+17,599
| New | +$420K | ﹤0.01% | 2620 |
|